神经重症患者左乙拉西坦剂量优化:Neuro-ARC研究
这项多中心前瞻性观察研究纳入50例危及生命的神经系统疾病患者,其中35例(70%)存在增强肾清除(ARC)。ARC组左乙拉西坦谷浓度显著低于无ARC组(中位数4.4 vs 11.8 mg/L,P=0.039)。群体药代动力学建模显示左乙拉西坦清除率为4.6±2.97 L/h,分布容积0.56±0.63 L/kg,符合一室模型,测得肌酐清除率(mCLCR)显著影响药物清除。蒙特卡洛模拟提示初始500 mg每日两次剂量不足,mCLCR≥90 mL/min/1.73 m²(包括ARC)者可能至少需1500 mg每日两次,mCLCR 60-89 mL/min/1.73 m²者可能需要初始1250 mg每日两次。
要点
- 神经重症患者中ARC发生率高(70%,35/50例),ARC组左乙拉西坦谷浓度中位数4.4 mg/L,显著低于无ARC组的11.8 mg/L(P=0.039)。
- 群体药代动力学显示左乙拉西坦清除率4.6±2.97 L/h,分布容积0.56±0.63 L/kg,mCLCR是显著影响清除率的协变量。
- 模拟显示初始500 mg每日两次剂量不足,mCLCR≥90 mL/min/1.73 m²(含ARC)者可能至少需1500 mg每日两次。
- mCLCR 60-89 mL/min/1.73 m²者可能需要初始剂量1250 mg每日两次。
- ARC通过增强清除显著影响左乙拉西坦药代动力学,神经重症患者需按mCLCR调整剂量。
适用人群与场景
- 参与中心收治的危及生命的神经系统疾病患者。
- 研究纳入50例神经重症患者,其中35例(70%)存在增强肾清除(ARC)。
诊断标准与关键阈值
- 增强肾清除(ARC)采用8小时尿液收集法测得的肌酐清除率(mCLCR)评估,研究按mCLCR≥90 mL/min/1.73 m²(包括ARC患者)和mCLCR 60-89 mL/min/1.73 m²分层给出剂量建议。
处置流程与药物剂量
- mCLCR≥90 mL/min/1.73 m²(包括ARC患者)者,左乙拉西坦初始剂量可能至少需1500 mg每日两次。
- mCLCR 60-89 mL/min/1.73 m²者,左乙拉西坦初始剂量可能需要1250 mg每日两次。
- 初始500 mg每日两次剂量不足。
研究设计与关键结果
- 多中心前瞻性观察研究纳入50例危及生命的神经系统疾病患者,每例最多采集4次血浆样本,用经验证的高效液相色谱法分析。
- 35例(70%)存在ARC,ARC组左乙拉西坦谷浓度中位数4.4 mg/L(四分位距11.5)vs 无ARC组11.8 mg/L(四分位距19),P=0.039。
- 群体药代动力学建模(Monolix软件)显示左乙拉西坦清除率4.6±2.97 L/h,分布容积0.56±0.63 L/kg,符合一室模型,mCLCR显著影响清除率。
- 蒙特卡洛模拟提示初始500 mg每日两次剂量不足;mCLCR≥90 mL/min/1.73 m²(含ARC)者可能至少需1500 mg每日两次,mCLCR 60-89 mL/min/1.73 m²者可能需要初始1250 mg每日两次。
证据类型、等级与局限
- 证据类型:多中心前瞻性观察研究。
- 局限:原文未报告局限性。
对床旁实践的改变
- 神经重症患者中ARC常见(70%),ARC组左乙拉西坦谷浓度显著低于无ARC组,提示对ARC患者需关注剂量不足。
- 模拟结果提示初始500 mg每日两次剂量不足,mCLCR≥90 mL/min/1.73 m²(含ARC)者可能至少需1500 mg每日两次,mCLCR 60-89 mL/min/1.73 m²者可能需要初始1250 mg每日两次。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Levetiracetam, a first-line antiseizure medication, is primarily eliminated through the kidneys, with approximately 66% renal elimination. Consequently, its pharmacokinetics are significantly influenced by kidney function. Augmented renal clearance (ARC), a condition characterized by renal hyperfiltration, is frequently observed in critical care settings and can profoundly impact the disposition of renally eliminated drugs such as levetiracetam. Our objectives were to characterize levetiracetam pharmacokinetics in neurocritical care patients, identify covariates significantly influencing drug clearance, and provide clinicians with optimal dosage recommendations in those with and without ARC.
METHODS: This was a multicenter, prospective, observational study involving patients admitted to the participating centers with life-threatening neurological illnesses. Each participant had up to four plasma samples collected, and the samples were analyzed using a validated high-performance liquid chromatography method. The creatinine clearance (CLCR) of enrolled participants was measured using the 8-h urine collection method (measured CLCR [mCLCR]). Population pharmacokinetic modeling was performed using Monolix software. Monte Carlo simulations were performed to explore various dosage strategies and to suggest optimal levetiracetam regimens.
RESULTS: Our study included 50 patients, with 35 patients (70%) experiencing ARC. Trough levetiracetam levels were significantly lower in the ARC group compared with the no-ARC group (median [interquartile range] 4.4 [11.5] vs. 11.8 [19] mg/L, p value = 0.039, respectively). Population pharmacokinetic modeling showed levetiracetam clearance at 4.6 ± 2.97 L/h and volume of distribution at 0.56 ± 0.63 L/kg, following a one-compartment model. The mCLCR significantly affected levetiracetam clearance. Simulations indicated that an initial 500 mg twice daily (BID) dosage is insufficient. Patients with mCLCR ≥ 90 mL/min/1.73 m2, including patients with ARC, may need at least 1500 mg BID, whereas those with mCLCR 60-89 mL/min/1.73 m2 may require an initial dosage of 1250 mg BID.
CONCLUSIONS: Augmented renal clearance significantly impacts the pharmacokinetics of levetiracetam by enhancing clearance. Dosing simulations revealed the inadequacy of the initial 500 mg BID regimen, indicating a minimum dosage of 1500 mg BID is necessary for patients experiencing ARC to achieve reference range concentrations.
参考来源
- Kharouba M, Cook AM, Bastin MLT, et al. Levetiracetam Dosing Optimization in Neurocritical Care Population: Neuro-ARC Study. Neurocrit Care. 2025. PMID: 40908416. doi:10.1007/s12028-025-02347-5
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。